Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer

BACKGROUND: An accurate and early diagnosis of bladder cancer (BC) is essential to offer patients the most appropriate treatment and the highest cure rate. For this reason, patients need to be best stratified by class and risk factors. We aimed to develop a score able to better predict cancer outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferro, Matteo, Di Mauro, Marina, Cimino, Sebastiano, Morgia, Giuseppe, Lucarelli, Giuseppe, Abu Farhan, Abdal Rahman, Vartolomei, Mihai Dorin, Porreca, Angelo, Cantiello, Francesco, Damiano, Rocco, Busetto, Gian Maria, Del Giudice, Francesco, Hurle, Rodolfo, Perdonà, Sisto, Borghesi, Marco, Bove, Pierluigi, Autorino, Riccardo, Crisan, Nicolae, Marchioni, Michele, Schips, Luigi, Soria, Francesco, Mari, Andrea, Minervini, Andrea, Veccia, Alessandro, Battaglia, Michele, Terracciano, Daniela, Musi, Gennaro, Cordima, Giovanni, Muto, Matteo, Mirone, Vincenzo, de Cobelli, Ottavio, Russo, Giorgio Ivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947442/
https://www.ncbi.nlm.nih.gov/pubmed/33718065
http://dx.doi.org/10.21037/tau-20-1272
Descripción
Sumario:BACKGROUND: An accurate and early diagnosis of bladder cancer (BC) is essential to offer patients the most appropriate treatment and the highest cure rate. For this reason, patients need to be best stratified by class and risk factors. We aimed to develop a score able to better predict cancer outcomes, using serum variables of inflammation. METHODS: A total of 1,510 high-risk non-muscle invasive bladder cancer (NMIBC) patients were included in this retrospective observational study. Patients with pathologically proven T1 HG/G3 at first TURBT were included. Systemic combined inflammatory score (SCIS) was calculated according to systemic inflammatory markers (SIM), modified Glasgow prognostic score (mGPS), and prognostic nutritional index (PNI) dichotomized (final score from 0 to 3). RESULTS: After 48 months of follow-up (IQR 40.0–73.0), 727 patients recurred (48.1%), 485 progressed (32.1%), 81 died for cancer (7.0%), and 163 died for overall causes (10.8%). Overall, 231 (15.3%) patients had concomitant Cis, 669 (44.3%) patients had multifocal pathology, 967 (64.1%) patients had tumor size >3 cm. Overall, 357 (23.6%) patients received immediate-intravesical therapy, 1,356 (89.8%) received adjuvant intravesical therapy, of which 1,382 (91.5%) received BCG, 266 (17.6%) patients received mitomycin C, 4 (0.5%) patients received others intravesical therapy. Higher SCIS was independently predictive of recurrence (hazard ratio HR 1.5, 1.3 and 2.2) and cancer specific mortality for SCIS 0 and 3 (HR: 1.61 and 2.3), and overall mortality for SCIS 0 and 3 (HR: 2.4 and 3.2). Conversely, SCIS was not associated with a higher probability of progression. CONCLUSIONS: The inclusion of the SCIS in clinical practice is simple to apply and can help improve the prediction of cancer outcomes. It can identify patients with high-grade BC who are more likely to experience disease mortality.

Ejemplares similares